IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST Action

Sandrine Lecour, Ioanna Andreadou, Hans Erik Bøtker, Sean M. Davidson, Gerd Heusch, Marisol Ruiz-Meana, Rainer Schulz, Coert J. Zuurbier, Péter Ferdinandy, Derek J. Hausenloy*, Pavle Adamovski, Saime Batirel, Monika Barteková, Luc Bertrand, Christophe Beauloye, David Biedermann, Vilmante Borutaite, Stefan Chlopicki, Maija Dambrova, Sean DavidsonYvan Devaux, Fabio Di Lisa, Dragan Djuric, David Erlinge, Ines Falcao-Pires, Eleftheria Galatou, Alfonso Garcia-Sosa, Henrique Girao, Zoltan Giricz, Mariann Gyongyosi, Derek J. Hausenloy, Donagh Healy, Vladimir Jakovljevic, Jelena Jovanic, George Kararigas, Risto Kerkal, Frantisek Kolar, Brenda Kwak, Przemysław Leszek, Edgars Liepinsh, Jacob Lonborg, Sarah Longnus, Jasna Marinovic, Danina Mirela Muntean, Lana Nezic, Michel Ovize, Pasquale Pagliaro, Clarissa Pedrosa Da Costa Gomes, John Pernow, Andreas Persidis, on behalf of the European Union-CARDIOPROTECTION COST ACTION CA16225

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

7 Citations (Scopus)

Abstract

Acute myocardial infarction (AMI) and the heart failure (HF) which may follow are among the leading causes of death and disability worldwide. As such, new therapeutic interventions are still needed to protect the heart against acute ischemia/reperfusion injury to reduce myocardial infarct size and prevent the onset of HF in patients presenting with AMI. However, the clinical translation of cardioprotective interventions that have proven to be beneficial in preclinical animal studies, has been challenging. One likely major reason for this failure to translate cardioprotection into patient benefit is the lack of rigorous and systematic in vivo preclinical assessment of the efficacy of promising cardioprotective interventions prior to their clinical evaluation. To address this, we propose an in vivo set of step-by-step criteria for IMproving Preclinical Assessment of Cardioprotective Therapies (‘IMPACT’), for investigators to consider adopting before embarking on clinical studies, the aim of which is to improve the likelihood of translating novel cardioprotective interventions into the clinical setting for patient benefit.

Original languageEnglish
Article number52
Pages (from-to)52
JournalBasic Research in Cardiology
Volume116
Issue number1
DOIs
Publication statusPublished - 13 Sep 2021

Keywords

  • Cardioprotection
  • Drug development
  • Infarction
  • Ischemia
  • Reperfusion

Fingerprint

Dive into the research topics of 'IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST Action'. Together they form a unique fingerprint.

Cite this